An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.

导出原文传递

翻译打印收藏纠错

作者： Takuro,Mizukami ^[1] ; Tempei,Miyaji ^[2] ; Yukiya,Narita ^[3] ; Tomohiro,Matsushima ^[4] ; Takashi,Ogura ^[5] ; Hiromichi,Miyagaki ^[6] ; Ryohei,Kawabata ^[6] ; Yoshiki,Horie ^[1] ; Takashi,Kawaguchi ^[7] ; Kei,Muro ^[3] ; Hiroki,Hara ^[4] ; Takuhiro,Yamaguchi ^[8] ; Takako,E Nakajima ^[1]

作者单位： Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, 216-8511, Japan. ^[1] Department of Clinical Trial Data Management, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan. ^[2] Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, 464-8681, Japan. ^[3] Department of Gastroenterology, Saitama Cancer Center, Saitama, 362-0806, Japan. ^[4] Department of Clinical Oncology, Kawasaki Municipal Tama Hospital, Kawasaki, 214-8525, Japan. ^[5] Department of Surgery, Osaka Rosai Hospital, Sakai, 591-8025, Japan. ^[6] Department of Practical Pharmacy, Tokyo University of Pharmacy & Life Sciences, Hachioji, 192-0392, Japan. ^[7] Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan. ^[8] Kyoto Innovation Center for Next-Generation Clinical Trials & iPS Cell Therapy, Kyoto University Hospital, Kyoto, 606-8507, Japan. ^[9]

关键词 FAACT PG-SGA advanced gastric cancer body weight loss nutrition nutrition counseling taxane and ramucirumab